<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996605</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00025901</org_study_id>
    <nct_id>NCT01996605</nct_id>
  </id_info>
  <brief_title>Efficacy of Spinal Oxytocin</brief_title>
  <official_title>Efficacy of Intrathecal Oxytocin in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James C. Eisenach, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of intrathecal oxytocin on areas and
      intensity of hyperalgesia and allodynia induced by topical capsaicin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: There is a strong experimental basis to support the study of oxytocin by the spinal
      route for analgesia in humans.  Oxytocin containing cells in the dorsal parvocellular
      division of the paraventricular nucleus (PVN) project to the spinal cord (1).  Noxious
      stimulation activates these cells via the A1 noradrenergic relay in the pons (2) and
      produces analgesia by spinal release of oxytocin, since intrathecal injection of an oxytocin
      receptor antagonist worsens pain behaviors from peripheral inflammation (3).  Direct
      electrical stimulation of the PVN reduces dorsal horn neuronal responses to noxious
      stimulation, and this is blocked by administration of sequestering antibody for oxytocin
      (4).  Similarly, direct electrical stimulation of the PVN reduces behavioral sensitivity in
      a model of chronic neuropathic pain, and this effect is blocked by an oxytocin receptor
      antagonist (5).  Intrathecal injection of oxytocin in normal rats reduces dorsal horn
      neuronal responses to noxious stimuli (6) as well as behavioral responses to noxious thermal
      (3), mechanical (3), and chemical (7) stimuli.  Finally, intrathecal injection of oxytocin
      in rat models of chronic pain also reduces dorsal horn neuronal responses to sensory
      stimulation (6) as well as behavioral responses to thermal (5) and mechanical (7) stimuli.

      Rationale: We anticipate that oxytocin will be effective after spinal injection in humans
      against chemical induced hypersensitivity states.

      Objectives: Determine the effect of intrathecal oxytocin on areas and intensity of
      hyperalgesia and allodynia induced by topical capsaicin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Hyperalgesia</measure>
    <time_frame>105 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The area of hyperalgesia after the first skin heating following topical capsaicin.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Evaluating the Efficacy of Intrathecal Oxytocin in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 15 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 150 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative free normal saline injected spinally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 15 mcg</intervention_name>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 150 mcg</intervention_name>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  weight &lt; 240 pounds

          -  American Society  of Anesthesiology Category 1 or 2

        Exclusion Criteria:

          -  allergy to oxytocin or lidocaine

          -  allergy to chilli peppers

          -  Females: active gynecological disease such as uterine fibroids or ongoing bleeding

          -  Pregnancy or currently breastfeeding

          -  Females that have delivered a baby within 2 years of study

          -  Taking prescription medications (exception: oral birth control medication)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Curry, RN</last_name>
      <phone>336-716-4294</phone>
      <email>recurry@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>James C Eisenach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>James C. Eisenach, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
